Journals / Türkderm Türk deri hastalıkları ve frengi arşivi / 2022 / Cilt: 56 - Sayı: 1

Biosimilars

Biyobenzerler

Pages
75–76
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

By lowering treatment costs, biosimilars may provide considerable economies for health systems that reimburse healthcare expenditures.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:For a drug to be defined as a biosimilar, it should be fairly similar to the previously approved original or reference product.
📊
Key Findings & Data:The minor variances in its inactive ingredients should not pose clinically significant differences from the reference product in terms of safety and efficacy potency.
💡
Conclusion & Impact:By lowering treatment costs, biosimilars may provide considerable economies for health systems that reimburse healthcare expenditures.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

For a drug to be defined as a biosimilar, it should be fairly similar to the previously approved original or reference product. The minor variances in its inactive ingredients should not pose clinically significant differences from the reference product in terms of safety and efficacy potency. Biosimilars of infliximab and adalimumab have received reimbursements in our country. By lowering treatment costs, biosimilars may provide considerable economies for health systems that reimburse healthcare expenditures.

Özet

Bir ilacın biyobenzer olarak tanımlanabilmesi için önceden onaylı orijinal veya referans ürüne oldukça benzer olması, inaktif bileşenlerindeki minör farklılıkların güvenlik, etkinlik ve potens açısından referans ürünle klinik olarak anlamlı farklılıklar yaratmaması gerekir. Ülkemizde infliksimab ve adalimumabın biyobenzerleri geri ödeme almıştır. Biyobenzerler tedavi maliyetini düşürerek geri ödeme sağlayan sağlık sistemlerinde önemli bir ekonomi sağlayabilirler

🔖

Cite This Article

BAŞKAN, E. B. (2022). Biosimilars. Türkderm Türk deri hastalıkları ve frengi arşivi, Cilt: 56 - Sayı: 1, 75–76. https://ajindex.com/articles/622422

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Carrascosa JM, Jacobs I, Petersel D, Strohal R: Biosimilar drugs for psoriasis: principles, present, and near future. Dermatol Ther (Heidelb) 2018;8:173- 94
  2. US Food and Drug Administration. (2015). Scientific con- siderations in demonstrating biosimilarity to a ref- erence product: guidance for industry. (Accessed: 9 Feb 2017). Available form: http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM291128.pdf 3. Kuhlmann M, Covic A: The protein science of biosimilars. Nephrol Dial Transplant 2006;21(Suppl5):v4-8
  3. Expert Committee on Biological Standardization. Guidelines on evaluation of similar biotherapeutic products (SBPs) 2009. Available form: http://www. who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_ FOR_WEB_22APRIL2010.pdf 5. Committee for Medicinal Products for Human Use (CHMP). (2014). Guideline on similar biological medicinal products containing biotechnology-derived pro- teins as active substance: non-clinical and clinical issues. Available form: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_ guideline/2015/01/WC 500180219.pdf 6. Reynolds KA, Pithadia DJ, Lee EB, Han G, Wu JJ: Are biosimilars approved for use in psoriasis safe enough to replace leading biologic therapies? A review. Expert Opin Drug Saf 2020;19:459-66
  4. Akyol M, Alper S, Atakan N, et al.: Türkiye Psoriasis Tedavi Kılavuzu. Turkderm - Arch Turk Dermatol Venerol 2016;50(Suppl1):1-56
  5. Cohen AD, Wu JJ, Puig L, et al.: Biosimilars for psoriasis: worldwide overview of regulatory guide- lines, uptake and implications for dermatology clinical practice. Br J Dermatol 2017;177:1495-502